Appropriate use of antimicrobial agents: Challenges and strategies for improvement

Critical Care Medicine

Volumn 31, Issue 2, 2003, Pages 608-616

  Niederman, Michael S ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Antimicrobial agents; Empirical therapy; Nosocomial pneumonia; Resistance

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFAMANDOLE; CEFIXIME; CEFOTAXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; FLUCONAZOLE; GATIFLOXACIN; GENTAMICIN; METICILLIN; MOXIFLOXACIN; OFLOXACIN; OXACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CLINICAL TRIAL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; LUNG LAVAGE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW;

ANTI-BACTERIAL AGENTS; DRUG UTILIZATION; HUMANS; INFECTION;

EID: 0037326679     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000050464.70382.D6     Document Type: Review

References (62)

1. Goldmann DA, Weinstein RA, Wenzel RP, et al: Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: A challenge to hospital leadership. The Workshop to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. JAMA 1996; 275:234-240
2. Polk R: Optimal use of modern antibiotics: Emerging trends. Clin Infect Dis 1999; 29:264-274
3. Wenzel RP, Edmond MB: Vancomycin-resistant Staphylococcus aureus: Infection control considerations. Clin Infect Dis 1998; 27:245-251
4. Carling PC, Fung T, Coldiron JS: Parenteral antibiotic use in acute-care hospitals: A standardized analysis of fourteen institutions. Clin Infect Dis 1999; 29:1189-1196
5. Marr JJ, Moffet HL, Kunin CM: Guidelines for improving the use of antimicrobial agents in hospitals: A statement by the Infectious Diseases Society of America. J Infect Dis 1988; 157:869-876
6. Mehta RM, Radu OA, Pollack S, et al: Natural history and variability of respiratory isolates and antimicrobial susceptibility in a medical ICU. Abstr. Chest 2000; 118(Suppl):178S
7. Pharmaceutical companies are working on 137 new ways to thwart infectious diseases, says PhRMA survey. Available at: http://www.phrma.org/press/newsreleases/2000-10-31.182.phtml. Accessed July 30, 2001
8. Byl B, Clevenbergh P, Jacobs F, et al: Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis 1999; 29:60-66
9. Shlaes DM, Gerding DN, John JF Jr, et al: Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25:584-599
10. Rello J, Sa-Borges M, Correa H, et al: Variations in etiology of ventilator-associated pneumonia across four treatment sites: Implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999; 160:608-613
11. Goldmann DA, Huskins WC: Control of nosocomial antimicrobial-resistant bacteria: A strategic priority for hospitals worldwide. Clin Infect Dis 1997; 24(Suppl 1):S139-S145
12. Gross PA: The potential for clinical guidelines to impact appropriate antimicrobial agent use. Infect Dis Clin North Am 1997; 11:803-812
13. Gyssens IC, Blok WL, van den Broek PJ, et al: Implementation of an educational program and an antibiotic order form to optimize quality of antimicrobial drug use in a department of internal medicine. Eur J Clin Microbiol Infect Dis 1997; 16:904-912
14. Hyatt JM, Schentag JJ: Potential role of pharmacokinetics, pharmacodynamics, and computerized databases in controlling bacterial resistance. Infect Control Hosp Epidemiol 2000; 21(Suppl):S18-S21
15. Schentag JJ: Antimicrobial action and pharmacokinetics: The use of AUIC to improve efficacy and avoid resistance. J Chemother 1999; 11:426-439
16. Reichler MR, Rakovsky J, Sobotová A, et al: Multiple antimicrobial resistance of pneumococci in children with otitis media, bacteremia, and meningitis in Slovakia. J Infect Dis 1995; 171:1491-1496
17. Archibald L, Phillips L, Monnet D, et al: Antimicrobial resistance in isolates from inpatients and outpatients in the United States: Increasing importance of the intensive care unit. Clin Infect Dis 1997; 24:211-215
18. Fridkin SK, Steward CD, Edwards JR, et al: Surveillance of antimicrobial use and antimicrobial resistance in United States Hospitals: Project ICARE Phase 2. Clin Infect Dis 1999; 29:245-252
19. White AC Jr, Atmar RL, Wilson J, et al: Effects of requiring prior authorization for selected antimicrobials: Expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997; 25:230-239
20. Morgan AS, Brennan PJ, Fishman NO: Impact of a vancomycin restriction policy on use and cost of vancomycin and incidence of vancomycin-resistant Enterococcus. Ann Pharmacother 1997; 31:970-973
21. Lesch CA, Itokazu GS, Danziger LH, et al: Multi-hospital analysis of antimicrobial usage and resistance trends. Diagn Microbiol Infect Dis 2001; 41:149-154
22. National Nosocomial Infections Surveillance (NNIS) Report. Data Summary from October-April 1997: A Report From the NNIS System. Hospital Infections Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, US Department of Health and Human Services, Atlanta, Georgia. Am J Infect Control 1997; 1986:25:477-487
23. Jones RN, Low DE, Pfaller MA: Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn Microbiol Infect Dis 1999; 33:101-112
24. Vincent J-L, Bihari DJ, Suter PM, et al: The prevalence of nosocomial infection in intensive care units in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) study. The EPIC International Advisory Committee. JAMA 1995; 274:639-644
25. Kollef MH, Sherman G, Ward S, et al: Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-474
26. Luna CM, Vujacich P, Niederman MS, et al: Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111:676-685
27. Modai J: Empiric therapy of severe infections in adults. Am J Med 1990; 88(Suppl 4A):12S-17S
28. Meehan TP, Fine MJ, Krumholz HM, et al: Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278:2080-2084
29. Niederman MS: The principles of antibiotic use and the selection of empiric therapy for pneumonia. In: Pulmonary Diseases and Disorders. Third Edition. Fishman A (Ed). New York, McGraw-Hill, 1997, pp 1939-1949
30. Hanes SD, Wood GC, Herring V, et al: Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000; 179:436-440
31. Hatala R, Dinh T, Cook DJ: Once-daily aminoglycoside dosing in immunocompetent adults: A meta analysis. Ann Intern Med 1996; 124:717-725
32. Preston SL, Drusano GL, Berman AL, et al: Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials. JAMA 1998; 279:125-129
33. Forrest A, Nix DE, Ballow CH, et al: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-1081
34. Quintiliani R, Cooper BW, Briceland LL, et al: Economic impact of streamlining antibiotic administration. Am J Med 1987; 82(Suppl 4A):391-394
35. Singh N, Rogers P, Atwood CW, et al: Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162:505-511
36. Ibrahim EH, Ward S, Sherman G, et al: Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2002; 30:266
37. Briceland LL, Nightingale CH, Quintiliani R, et al: Antibiotic streamlining from combination therapy to monotherapy utilizing an interdisciplinary approach. Arch Intern Med 1988; 148:2019-2022
38. American Thoracic Society: Hospital-acquired pneumonia in adults: Diagnosis assessment of severity, initial antimicrobial therapy and preventative strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med 1996; 153:1711-1725
39. Przybylski KG, Rybak MJ, Martin PR, et al: A pharmacist-initiated program of intravenous to oral antibiotic conversion. Pharmacotherapy 1997; 17:271-276
40. Bartlett JG, Breiman RF, Mandell LA, et al: Community-acquired pneumonia in adults: Guidelines for management. Clin Infect Dis 1998; 26:811-838
41. Chan R, Hemeryck L, O'Regan M, et al: Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: Open, randomised controlled trial. BMJ 1995; 310:1360-1362
42. Ramirez JA, Bordon J: Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med 2001; 161:848-850
43. Al-Eidan FA, McElnay JC, Scott MG, et al: Sequential antimicrobial therapy: Treatment of severe lower respiratory tract infections in children. J Antimicrob Chemother 1999; 44:709-715
44. Omidvari K, de Boisblanc BP, Karam G, et al: Early transition to oral antibiotic therapy for community-acquired pneumonia: Duration of therapy, clinical outcomes, and cost analysis. Respir Med 1998; 92:1032-1039
45. Siegel RE, Halpern NA, Almenoff PL, et al. A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia: The optimal duration of therapy. Chest 1996; 110:965-971
46. Ramirez JA, Srinath L, Ahkee S, et al: Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155:1273-1276
47. Dominguez EA, Smith TL, Reed E, et al: A pilot study of antibiotic cycling in a hematology-oncology unit. Infect Control Hosp Epidemiol 2000; 21(Suppl):S4-S8
48. Gerding DN: Antimicrobial cycling: Lessons learned from the aminoglycoside experience. Infect Control Hosp Epidemiol 2000; 21(Suppl):S12-S17
49. Gruson D, Hilbert G, Vargas F, et al: Rotation and restricted use of antibiotics in a medical intensive care unit: Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria. Am J Respir Crit Care Med 2000; 162:837-843
50. Lavin BS: Antibiotic cycling and marketing into the 21st century: A perspective from the pharmaceutical industry. Infect Control Hosp Epidemiol 2000; 21(Suppl):S32-S35
51. Raymond DP, Pelletier SJ, Crabtree TD, et al: Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit Care Med 2001; 29:1101-1108
52. McGowan JE Jr: Minimizing antimicrobial resistance in hospital bacteria: Can switching or cycling drugs help? Infect Control 1986; 7:573-576
53. Niederman MS: Is "crop rotation" of antibiotics the solution to a "resistant" problem in the ICU? Am J Respir Crit Care Med 1997; 156:1029-1031
54. Gerding DN, Larson TA, Hughes RA, et al: Aminoglycoside resistance and aminoglycoside usage: Ten years of experience in one hospital. Antimicrob Agents Chemother 1991; 35:1284-1290
55. John JF Jr, Rice LB: The microbial genetics of antibiotic cycling. Infect Control Hosp Epidemiol 2000; 21(Suppl):S22-S31
56. McGowan JE Jr: Strategies for study of the role of cycling on antimicrobial use and resistance. Infect Control Hosp Epidemiol 2000; 21(Suppl):S36-S43
57. Anglim AM, Klym B, Byers KE, et al: Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin-resistant Enterococcus faecium. Arch Intern Med 1997; 157:1132-1136
58. Lipsky BA, Baker CA, McDonald LL, et al: Improving the appropriateness of vancomycin use by sequential interventions. Am J Infect Control 1999; 27:84-90
59. Rahal JJ, Urban C, Horn D, et al: Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280:1233-1237
60. Chen DK, McGeer A, de Azavedo JC, et al: Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada: The Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341:233-239
61. Hyatt JM, Schentag JJ: Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 2000; 21(Suppl):S9-S11
62. Nicolau DP: Using pharmacodynamic and pharmacokinetic surrogate markers in clinical practice: Optimizing antimicrobial therapy in respiratory-tract infections. Am J Health Syst Pharm 1999; 56(Suppl 3):S16-S20